CurrentAetnaPolicy 0131

Clotting Factors

Clinical policy governing medical necessity and precertification requirements for clotting factor products for Aetna commercial medical plans; affects prescribing providers and members enrolled in applicable plan designs.

Policy Summary

PayerAetna

PolicyClotting Factors

Policy CodePolicy 0131

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionPrecertification of clotting factors is required of all Aetna participating providers and members in applicable plan designs.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>15distinct clotting factor products or product groups named

Precertification requiredprecertification requirement for participating providers

Prescriber specialty requiredmust be prescribed by or in consultation with a hematologist

Age restrictionSevenfact excludes members <12 years

continuation criteriaContinuation of therapy specified

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Recombinant FVIIa (NovoSeven RT, Sevenfact) — Initial Approval Criteria

ALL of the following

NovoSeven RT (coagulation factor VIIa [recombinant]) is covered when used for FDA‑approved indications, including: acquired hemophilia; acquired von Willebrand syndrome when other therapies failed to control the member’s condition (e.g., desmopressin or factor VIII/von Willebrand factor); congenital factor VII deficiency; Glanzmann’s thrombasthenia; hemophilia A or B with inhibitors when inhibitor titer ≥ 5 BU/mL or a history of ≥ 5 BU; and inhibitors to factor XI.
Sevenfact (coagulation factor VIIa [recombinant]-jncw) is covered when used for FDA‑approved indications in adults and adolescents (≥12 years): treatment and control of bleeding episodes in hemophilia A or B with inhibitors. Note: Sevenfact is not indicated for congenital factor VII deficiency and coverage will not be provided for members <12 years of age.
For both NovoSeven RT and Sevenfact, all other indications are considered experimental and investigational and will not be covered (see Experimental and Investigational section).
Prescriber requirement: must be prescribed by or in consultation with a hematologist.

FEIBA in Cardiac Surgery — Evidence and Operational Considerations

Aetna’s stance on FEIBA use in cardiac surgery is informed by limited and mixed evidence. Coverage for FEIBA in cardiac surgery is not a routine approved indication in Section II; the following summarizes the evidence and operational considerations relevant to requests for FEIBA in the cardiac surgery setting:

ALL of the following

Evidence summary: Small randomized pilot trials and observational studies report feasibility, potential reductions in transfusion requirements and re‑exploration, and low incidence of complications in selected patients; however, the body of evidence is limited, heterogeneous, and insufficient to establish definitive safety and effectiveness for routine use in cardiac surgery.
Systematic reviews and recent analyses conclude there is insufficient robust evidence to make definitive conclusions regarding the safety or effectiveness of FEIBA as a hemostatic agent in adult cardiac surgery. Concerns include possible thrombotic complications and inconsistent outcome benefits across studies.
Clinical use approach: FEIBA may be considered on a case‑by‑case, rescue basis for refractory, life‑threatening bleeding after cardiac surgery when conventional hemostatic measures (surgical control, blood component therapy, tranexamic acid/aminocaproic acid, and goal‑directed factor/platelet replacement guided by point‑of‑care testing) have failed, and when the expected benefits are judged to outweigh thrombotic risks.

Relevant Billing and Diagnostic Codes

Other CPT codes related to CPB / VWD diagnostic CPTsCPT

85002	Bleeding time
85335	Factor inhibitor test
85610-85611	Prothrombin time, and substitution, plasma fractions, each
85730-85732	Thromboplastin time, partial (PTT); plasma or whole blood, and substitution, plasma fractions, each
96365-96379	Therapeutic, prophylactic, and diagnostic injections and infusions
99601	Home infusion/specialty drug administration, per visit (up to 2 hours)
99602	each additional hour
S9345	Home infusion therapy, antihemophilic agent infusion therapy, per diem
0279U	VWF and collagen III binding ELISA, plasma
0280U	VWF and collagen IV binding ELISA, plasma

1–10 of 12

1/2

HCPCS injection codes for clotting factors and reversal agentsHCPCSCovered

J7182	Injection, factor VIII (recombinant) (NovoEight)
J7185	Injection, factor VIII (Xyntha), per IU
J7186	Injection, antihemophilic factor VIII / von Willebrand factor complex (human), per factor VIII i.u.
J7187	Injection, von Willebrand factor complex (Humate-P), per IU vWF-RCO
J7190	Factor VIII per IU (human or porcine)
J7192	Factor VIII recombinant per IU, NOS
J7204	Injection, factor VIII (Esperoct), per IU
J7208	Injection, factor VIII (Jivi), 1 IU
J7170	Injection, emicizumab-kxwh, 0.5 mg (Hemlibra)
J7188	Injection, factor VIII (Obizur), per IU

1–10 of 25

1/3

ICD-10 diagnosis codes referencedICD-10

D66	Hereditary factor VIII deficiency [Hemophilia A]
D67	Hereditary factor IX deficiency [Hemophilia B]
D68.01	Von Willebrand disease, type 1
D68.020	Von Willebrand disease, type 2A
D68.021	Von Willebrand disease, type 2B
D68.022	Von Willebrand disease, type 2M
D68.023	Von Willebrand disease, type 2N
D68.03	Von Willebrand disease, type 3
D68.311	Acquired hemophilia [acquired hemophilia A]
D68.2	Hereditary deficiency of other clotting factors

1–10 of 12

1/2

No billing codes in this excerptmixed

No codes listed

Inhibitor titer threshold — Bethesda units

Inhibitor titer threshold>= 5 Bethesda units per milliliter (BU/mL)

Measurement unitBethesda units per milliliter (BU/mL)

Clinical useRequired threshold for FEIBA, NovoSeven RT, and Sevenfact coverage for hemophilia with inhibitors

Baseline Factor X assay level for perioperative management

Baseline Factor X assay level (perioperative)>= 1%

ContextRequired for perioperative management coverage with Coagadex in hereditary Factor X deficiency

ApplicationMember must have baseline Factor X assay >=1% to meet perioperative management initial approval criteria

Target Factor levels — examples

Pre-surgery target (Factor X, Coagadex)Raise plasma Factor X to 70–90 IU/dL pre-surgery

Post-surgery maintenance (Factor X)Maintain plasma Factor X >=50 IU/dL until no longer at bleeding risk

Prophylaxis trough targetMonitor trough Factor X >=5 IU/dL for prophylaxis and adjust dose; do not exceed peak 120 IU/dL

Factor VIII level targets for bleeding severity

Minor–moderate bleeding target (FVIII)20–60 IU/dL (IU/dL or % of normal)

Major bleeding target (FVIII)60–100 IU/dL (IU/dL or % of normal)

Example dosing guidance (Jivi/Esperoct)Product-specific regimens and formulas provided; calculate dose to achieve target FVIII level using product multiplier (see product labeling)

AT activity goal (ATryn)

AT activity goal (ATryn)80% - 120% (0.8 - 1.2 IU/mL)

Dosing principleIndividualize dose based on pretreatment functional AT activity and body weight with therapeutic drug monitoring

MonitoringUse validated AT activity assay to guide dosing and maintain goal range

Severe hemophilia definition

Severe hemophilia definition< 1% factor activity (<0.01 IU/mL)

Clinical implicationPrimary prophylaxis usually indicated for patients with <1% activity to maintain trough >1% between doses

Source classificationAppendix A classification of hemophilia by factor activity

Factor VIII activity targets and dosing conversions

IU/kg to % rise conversion1 IU/kg raises FVIII level by approximately 2 IU/dL (2% of normal)

Dosing formula (Adynovate/Esperoct)Dose (IU) = body weight (kg) × desired FVIII increase (IU/dL or % of normal) × product-specific multiplier (commonly 0.5 IU/kg per IU/dL)

Practical noteUse product labeling/recovery to select the appropriate multiplier; Jivi provides recovery-based reciprocal guidance

Perioperative FVIII:C target

Perioperative FVIII:C target — minor surgery30 IU/dL

Perioperative FVIII:C target — major surgery60 IU/dL

Perioperative practice noteAssess FVIII:C within 3 hours pre-surgery to ensure targets met; administer Vonvendi with FVIII per labeling when indicated

Baseline FVIII threshold for co-administration with Vonvendi

Baseline FVIII threshold for Vonvendi co-administrationAdminister first Vonvendi dose with factor VIII if baseline FVIII < 40% or unknown

Initial dosing guidancePrescribing information recommends initial Vonvendi dose 40–80 IU/kg, adjusted by bleed severity

MonitoringMeasure FVIII:C and VWF activity; assay for inhibitors if expected levels not attained

pH threshold impacting rFVIIa utility

pH threshold impacting rFVIIa utilitypH < 7.1 reduces utility of rFVIIa

Clinical contextLow pH and severity of clinical bleeding predict reduced response to rFVIIa in registry and observational data

ImplicationConsider physiologic correction (e.g., acidosis) when evaluating rFVIIa use for refractory bleeding

Tretten target trough FXIII activity

Tretten trough FXIII activity target>= 10%

Tretten dosing35 IU/kg once monthly for routine prophylaxis to achieve trough >=10% (adjust if inadequate coverage)

MonitoringUse a validated FXIII activity assay to confirm trough target

Severe hemophilia factor activity (emphasis)

Severe hemophilia (duplicate emphasis)< 1% factor activity (<0.01 IU/mL)

Clinical relevanceAssociated with frequent spontaneous bleeding into joints and muscles; often indicates need for prophylaxis

ReferenceAppendix A classification

Moderate hemophilia factor activity

Moderate hemophilia definition1% to 5% factor activity

Bleeding patternOccasional spontaneous bleeding; severe bleeding with trauma or surgery

Clinical implicationMay require treatment for bleeding and consideration for prophylaxis based on bleeding phenotype

Mild hemophilia factor activity

Mild hemophilia definition6% to 40% factor activity

Bleeding patternBleeding usually with serious injury, trauma, or surgery; desmopressin may be effective in some patients

Management noteConsider desmopressin trial or factor replacement for procedures or significant bleeding

Prior Authorization, Documentation, and Clinical Actions

Prior Authorization

Precertification Required

Precertification required for Aetna participating providers and members for clotting factors. Contact Aetna Special Case Precert Unit at (855) 888-9046. Failure to obtain precertification may lead to denial of coverage.

Precertification required for participating providers

Prior Authorization

Match Use to FDA‑Approved Indication

Match requests to FDA‑approved, product‑specific indications. Examples: Andexxa is approved for reversal of apixaban or rivaroxaban (andexanet alfa dosing per label); idarucizumab (Praxbind) is approved for reversal of dabigatran (5 g IV for emergency/urgent indications); Tretten is approved for prophylaxis in congenital FXIII A‑subunit deficiency (35 IU/kg monthly, target trough ≥10%); Coagadex, Corifact, Vonvendi, Idelvion, Rixubis, Sevenfact and others should be used only for their labeled indications and age groups. Document the specific FDA indication and align dosing/regimen with the prescribing information.

Andexxa: reversal for apixaban/rivaroxaban (not for other FXa inhibitors)
Idarucizumab (Praxbind): 5 g IV for dabigatran reversal in emergency surgery/urgent procedures or life‑threatening bleeding
Tretten: prophylaxis for congenital FXIII A‑subunit deficiency, 35 IU/kg monthly, target trough ≥10%
Vonvendi: adult VWD indications per label
Coagadex: hereditary Factor X deficiency indications

Denial Risk

Off‑Label / Experimental Use Restriction

Off‑label or experimental uses are restricted. Aetna considers uses outside the FDA‑approved indications investigational and may deny coverage (examples: Tretten for non‑congenital FXIII indications, ATryn/Thrombate III outside listed uses, Andexxa or Praxbind for non‑labeled anticoagulants, Jivi in children <12 or previously untreated persons). Requests for investigational/experimental uses should reference clinical trial protocols; absence of supportive evidence may result in denial.

Jivi considered investigational for children <12 and previously untreated persons
Use of reversal agents outside labeled anticoagulants considered investigational

Denial Risk

Hypersensitivity / Contraindications

Contraindications and serious safety risks must be documented and monitored. Discontinue product and seek medical intervention for life‑threatening immediate hypersensitivity or anaphylaxis. Many products are contraindicated in patients with known life‑threatening hypersensitivity to the product or components (examples: Kovaltry/Nuwiq/Idelvion/Vonvendi/Coagadex/Obizur/Sevenfact). Document allergy history (including animal protein/rabbit/hamster sensitivities) prior to use.

Discontinue if life‑threatening hypersensitivity occurs
Document allergy history (e.g., hamster, rabbit proteins)

Denial Risk

Hemlibra Thrombotic Risk and Laboratory Interference

Hemlibra (emicizumab‑kxwh) carries a boxed warning for thrombotic microangiopathy and thromboembolism when used with high cumulative doses of activated prothrombin complex concentrate (aPCC). Avoid or limit concomitant aPCC (cumulative >100 U/kg/24 hrs) in patients on Hemlibra; document prior and concomitant therapy and monitor for thrombotic signs.

Black box warning: thrombotic microangiopathy and thromboembolism with cumulative aPCC >100 U/kg/24 hrs during Hemlibra prophylaxis
Hemlibra interferes with several coagulation assays—coordinate testing

Denial Risk

Off‑Label Use Thrombotic Risk and Restriction

Recombinant activated factor VII (rFVIIa) and other off‑label hemostatic uses are associated with increased arterial thromboembolic events, particularly in elderly patients. Use for non‑hemophilic indications should be restricted to clinical trials or reserved as rescue therapy when conventional measures fail; document attempts at standard therapies before use.

Off‑label rFVIIa increases arterial thromboembolism risk especially age ≥65
Reserve off‑label rFVIIa for rescue after standard interventions fail and document prior measures

Documentation Required

Laboratory‑Clinician Communication and Assay Selection

Communicate with the clinical laboratory to ensure appropriate assays are used for monitoring EHL and modified factor products. Some products interfere with routine clotting assays (e.g., Hemlibra) and measurement biases with EHL products can lead to large under‑ or over‑estimations; coordinate assay selection and interpretation.

Ensure lab uses validated chromogenic or one‑stage assays appropriate for the specific product
Document which assay was used and communicate desired monitoring targets

Documentation Required

Required Documentation and Clinical Justification

Document required safety and clinical elements with all prior authorization requests: diagnosis and indication, age, weight, prior therapies/trials (e.g., desmopressin trial or contraindication), previous response to factor products, inhibitor status and assay results, dosing and administration details, and allergy history. For rescue/off‑label rFVIIa, document failure of conventional therapies.

Include factor assay levels and inhibitor testing when expected activity not attained
Document desmopressin insufficiency or contraindication when applicable
For Tretten, document diagnosis and dosing rationale (35 IU/kg monthly target trough ≥10%)

Dosing and Administration Regimens

Scenario	Reported regimen / example dosing	Coverage status
Diffuse alveolar hemorrhage (adult series)
Intravenous rFVIIa 35–120 mcg/kg every 2 hours until hemostasis (mean total dose to control bleeding reported ~5 ± 3 mg)
experimental
Pediatric ICU intractable DAH — stepwise nebulized therapy
Nebulized tranexamic acid first; if inadequate response, add nebulized rFVIIa 35 mcg/kg (children <25 kg) or 50 mcg/kg (children >25 kg) per dose (added after 3–4 doses of n‑TXA); reported cessation in some patients
experimental
Intrapulmonary (endobronchial) instillation for refractory DAH
Intrapulmonary rFVIIa instillation divided between lungs at doses of 30, 50, or 60 mcg/kg; single or repeated doses based on response
experimental

Indication	Dosing / monitoring details from studies	Coverage status
On‑demand treatment of bleeding episodes (hereditary Factor X deficiency)
Mean in‑vivo recovery ~2.0 IU/dL per IU/kg; single‑infusion control in majority of treated bleeds; median dose per infusion reported ~31.7 IU/kg (range 24.6–38.8 IU/kg)
covered
Routine prophylaxis (children <12 years in trial)
Initial loading 50 IU/kg with 30‑minute post‑dose incremental recovery assessment; maintenance unit doses 40–50 IU/kg with trough Factor X measured during first 6 weeks and dose adjusted to maintain trough ≥5 IU/dL; median dosing interval ~3 days (range 2–8 days)
covered
Pharmacokinetics
Half‑life approximately 30 hours; monitor trough levels and adjust dosing to maintain trough ≥5 IU/dL; do not exceed peak targets as per labeling
covered

Product	FDA‑approved use (as stated)	Coverage status
Corifact (Factor XIII concentrate [human])
Indicated in adults and pediatric patients with congenital factor XIII deficiency for routine prophylactic treatment and peri‑operative management of surgical bleeding
covered

Covered uses with product-specific dosing (duplicate)

Covered uses with product‑specific dosing (duplicate reference for regimen details and dosing guidance):

Product‑indication alignment (duplicate): Use consistent with the product's approved indications and dosing recommendations; calculate doses using weight‑based formulas and monitor factor activity when dosing to targets.

See product dosing examples: Esperoct, Jivi, Alphanate, Coagadex, NovoSeven RT.

Place in Therapy and Salvage Options

salvage — single top-level node describing salvage use of agents

Salvage use — single top‑level node describing salvage use of agents:

Salvage use: Use of rFVIIa (intravenous, nebulized, or intrapulmonary) may be considered as salvage therapy for life‑threatening or refractory bleeding (e.g., diffuse alveolar hemorrhage) when conventional therapies have failed.

Examples: IV rFVIIa 35–120 mcg/kg q2h until hemostasis; nebulized rFVIIa 35–50 mcg/kg after failure of nebulized TXA; intrapulmonary instillation 30–60 mcg/kg. Evidence limited to case series, pilot trials and small retrospective studies.

salvage (alternate reference) — single top-level node

Alternate reference for salvage use (single top‑level node):

Salvage use (alternate): In life‑threatening pulmonary hemorrhage (DAH) or refractory postoperative bleeding, intrapulmonary or systemic rFVIIa has been used as a salvage measure after standard care failed; reported dosing and routes vary and require individualized multidisciplinary decision‑making.

Document prior standard interventions and rationale for salvage therapy.

Examples reported for salvage dosing and administration in DAH and other salvage contexts

Examples reported for salvage dosing and administration in DAH and other salvage contexts (informational):

Reported salvage regimens: Examples include intravenous rFVIIa 35–120 mcg/kg every 2 hours until hemostasis; nebulized rFVIIa 35–50 mcg/kg/dose after failure of nebulized tranexamic acid; intrapulmonary instillation doses 30–60 mcg/kg with dosing frequency individualized to response.

Evidence from small case series, pilot studies and institutional reports; not routine standard of care.

Background and Evidence Summary

This policy addresses hereditary and acquired bleeding disorders commonly managed with clotting factor products, including hemophilia A and B (congenital factor VIII or IX deficiency), von Willebrand disease (VWD), acquired hemophilia A, and less common coagulation factor deficiencies such as factor X and factor XIII deficiency. It also covers adjunctive agents including bypassing products (e.g., FEIBA, rFVIIa), antithrombin replacement (ATryn, Thrombate III), and reversal agents (Andexxa, idarucizumab) where indicated.

Prescribing and management decisions in these disorders often depend on disease severity, prior response to therapies (for example desmopressin), laboratory testing (factor activity levels, inhibitor titers), and product‑specific labeled indications and age approvals.

Randomized trials and systematic reviews support the benefit of prophylactic clotting factor replacement versus on‑demand therapy in reducing bleeding frequency and improving joint outcomes in persons with hemophilia. Multiple RCTs and meta‑analyses show lower annualized bleeding rates with prophylaxis across low, intermediate, and high dosing regimens, though certainty ranges from very low to moderate and trial heterogeneity limits precision.

Product‑specific prophylaxis regimens have demonstrated efficacy in clinical programs (for example, Esperoct Q4D in adolescents/adults; various regimens in Factor VIII and IX programs). Selection of prophylactic regimen and dosing should align with the evidence base and the product's FDA‑approved dosing where applicable.

Clinical trials report indication‑specific efficacy metrics used to support coverage. Examples include Esperoct prophylaxis in adolescents/adults (50 IU/kg every 4 days) with a median ABR ~1.2 and pediatric prophylaxis (~65 IU/kg twice weekly) with median ABR ~2.0; Esperoct perioperative data showed hemostatic effect rated 'excellent' or 'good' in 95.6% of surgeries.

Jivi (PROTECT VIII) demonstrated reduced ABR across tailored prophylactic regimens and provided effective perioperative hemostasis in treated subjects; surgical hemostasis was rated 'good' or 'excellent' in reported cases. Nuwiq clinical programs reported mean or median prophylactic ABRs ~1.2–1.5 and high proportions of bleeds treated successfully with routine therapy.

Systematic reviews and RCTs summarized in the evidence base indicate prophylaxis decreases joint bleeds and total bleeding events compared with episodic treatment; however, study heterogeneity and variable certainty of evidence require individualized dosing and monitoring decisions aligned with product labeling.

Evidence for off‑label uses of recombinant Factor VIIa (rFVIIa) is principally observational and consists of case series, registries, pilot studies, and small retrospective cohorts. Reported settings include diffuse alveolar hemorrhage (DAH), refractory gastrointestinal bleeding after hematopoietic stem cell transplant, and selected qualitative platelet disorders (e.g., Glanzmann thrombasthenia) where conventional therapies failed.

Registry and case series data report high rates of bleeding cessation in many series (for example, DAH and GI bleeding), but randomized evidence is limited and safety concerns—particularly arterial thromboembolic events—have been reported. Accordingly, rFVIIa use outside its labeled hemophilia indications is considered experimental or may be reserved as rescue therapy in life‑threatening, refractory bleeding after standard measures have failed.

FEIBA has been used as an empirical rescue therapy for refractory bleeding after cardiopulmonary bypass (CPB) in adult cardiac surgery. A small randomized pilot trial and systematic literature reviews exist, but evidence is insufficient to draw definitive conclusions about safety or effectiveness in this setting. Concerns include potential thrombotic complications.

Because available data are limited and larger conclusive trials are lacking, FEIBA for cardiac surgery bleeding remains a context‑specific, investigational rescue strategy rather than a routine, evidence‑based indication.

Kcentra (4‑factor PCC) evidence includes a small randomized crossover study in healthy volunteers showing partial normalization of thrombin generation after 25 U/kg in the setting of apixaban exposure. Clinical trial data supporting Kcentra's FDA indication derive from studies in patients requiring urgent VKA reversal with major bleeding.

Kcentra is indicated for urgent reversal of vitamin K antagonist–induced acquired coagulation factor deficiency in adults with acute major bleeding; evidence for use in DOAC‑associated bleeding is limited to proof‑of‑concept physiologic studies and observational reports, and Kcentra is not indicated for VKA reversal in patients without acute major bleeding.

Definitions and Terminology

Inhibitor titer — BU/mL and threshold references

Inhibitor titer unit and threshold referenceMeasured in Bethesda units per milliliter (BU/mL); several products require >=5 BU/mL for coverage (FEIBA, NovoSeven RT, Sevenfact)

Clinical implicationPerform Bethesda or appropriate inhibitor assays if expected FVIII activity not attained or bleeding uncontrolled

DocumentationDocument inhibitor titer in prior authorization/request to support bypassing agent coverage

Routine prophylaxis — definition and emicizumab mention

Routine prophylaxis definitionUse of a clotting factor product to prevent or reduce frequency of bleeding episodes (e.g., emicizumab/Hemlibra indicated for routine prophylaxis)

Product exampleEmicizumab (Hemlibra) is indicated for routine prophylaxis in hemophilia A with or without inhibitors

Continuation noteContinuation requires documentation of benefit and absence of combination with FVIII products for prophylaxis

VWF:CB/VWF:Ag ratio — assay definition

VWF:CB/VWF:Ag ratio assayAssesses VWF collagen binding relative to antigen; used to help diagnose type 2 VWD (2A, 2B, 2M) when additional testing is needed

RolePart of VWD subtyping algorithm to distinguish qualitative defects affecting collagen binding

GuidanceUse in conjunction with other VWF assays (VWF:RCo, VWF:GPIbR/GPIbM) per diagnostic recommendations

VWF:FVIII binding assay — diagnostic definition

VWF:FVIII binding assayAssay used to diagnose type 2N von Willebrand disease

IndicationMedically necessary when type 2N VWD is suspected

Diagnostic contextConsider alongside genetic testing or clinical suspicion of reduced FVIII binding

VWF platelet‑binding activity assays (VWF:GPIbM, VWF:GPIbR)

VWF platelet‑binding activity assaysIncludes VWF:GPIbM and VWF:GPIbR — assays measuring platelet‑binding activity of VWF used in VWD diagnosis

AdvantageNewer assays avoid ristocetin and have better sensitivity and lower variability than VWF:RCo

Use caseRecommended for platelet‑binding activity assessment per ASH/ISTH guidance when available

Dosage calculation — IU/kg × desired rise × product multiplier

Dosage calculation formulaDose (IU) = body weight (kg) × desired Factor increase (IU/dL or % normal) × product-specific multiplier

Common multiplier examples0.5 IU/kg per IU/dL for some FVIII products (e.g., Adynovate/Esperoct); Jivi uses empirical 2 IU/dL per 1 IU/kg recovery for calculations

Practical noteUse product labeling recovery/recommended multiplier rather than generic constants when available

Trough target — Coagadex monitoring target and peak limit

Coagadex trough monitoring target>= 5 IU/dL (trough) for prophylaxis

Peak limitDo not exceed a peak Factor X level of 120 IU/dL

Dosing contextAdjust dose based on trough level and clinical response; pediatric and adult dosing schedules provided in labeling

Severe hemophilia definition (<1% activity)

Severe hemophilia definition (concise)< 1% activity

Clinical noteIndicates high bleed risk and typical indication for primary prophylaxis

ReferenceAppendix A classification

Immune tolerance induction — definition and purpose

Immune tolerance induction — definitionAdministration of very high doses of replacement factor VIII or IX over extended periods to suppress or eradicate inhibitors and restore factor efficacy

PurposeTo eradicate neutralizing antibodies (inhibitors) allowing restoration of effective factor replacement therapy

Outcome noteApproximately 20–30% of patients may fail to respond to immune tolerance induction

100% FVIII dose defined as 50 IU/kg

100% FVIII dose definition50 IU/kg equals a 100% FVIII dose (attaining ~1.00 IU/mL FVIII activity)

UseReference point for calculating percentage rises and dosing regimens

SourceStandard pharmacokinetic dosing convention cited in background

Bypassing agents — definition and examples

Bypassing agents — definitionHemostatic agents used to control bleeding in patients with inhibitors (includes PCCs, rFVIIa, and activated PCCs like FEIBA)

ExamplesFEIBA (aPCC), NovoSeven RT (rFVIIa), Sevenfact (rFVIIa-jncw)

Clinical noteResponsiveness may vary; switching agents may be necessary if inadequate hemostasis

Extended half-life FVIII — definition

Extended half-life (EHL) FVIII — definitionRecombinant FVIII products modified to extend plasma half-life compared with standard products

ImplicationMay allow less frequent dosing but assay measurement caveats exist for some EHL products

ExamplesJivi, Esperoct and others in labeling discussed

FVIII inhibitor — definition and testing

FVIII inhibitor — definitionA neutralizing antibody that reduces or neutralizes administered FVIII efficacy; detection requires Bethesda or appropriate inhibitor assays

Testing recommendationPerform inhibitor assay if expected FVIII activity not attained or bleeding not controlled

Clinical consequencePresence of inhibitors may necessitate bypassing therapy or immune tolerance induction

Bypassing agent — definition

Bypassing agent — short definitionHemostatic agent (e.g., rFVIIa or aPCC) used to treat bleeding in hemophilia patients with inhibitors

Clinical useUsed when inhibitors prevent effective replacement factor therapy or when immune tolerance induction fails

Coverage noteProduct-specific criteria require inhibitor titer documentation for coverage

Acquired hemophilia A — definition and Obizur indication

Acquired hemophilia A — definitionAutoantibodies against factor VIII leading to bleeding; Obizur indicated for on-demand treatment in adults with acquired hemophilia A

Testing noteSafety/efficacy of Obizur not established if baseline anti-porcine FVIII inhibitor titer >20 BU

Clinical implicationTreatment requires specialist management and documentation

Hemlibra (emicizumab-kxwh) — definition and indication summary

Hemlibra (emicizumab-kxwh) — definitionA bispecific antibody directed to factor IXa and X indicated for routine prophylaxis in hemophilia A with or without FVIII inhibitors

Indication noteUsed for routine prophylaxis to prevent or reduce bleed frequency; discontinuation of prophylactic FVIII products after starting Hemlibra per labeling

Age rangeApproved for adults and pediatric patients including newborns per FDA labeling

Rebinyn (nonacog beta pegol) — definition

Rebinyn (nonacog beta pegol) — definitionA glycoPEGylated recombinant factor IX with extended half-life approved for treatment and perioperative management in hemophilia B

Clinical noteOnce-weekly prophylaxis regimens studied (e.g., 40 IU/kg), with trial-reported efficacy

UseApproved for prophylaxis and on‑demand treatment

Vonvendi — definition and indication summary

Vonvendi — definitionRecombinant von Willebrand factor indicated for on-demand treatment, perioperative management, and routine prophylaxis in adults with VWD

Administration noteIf baseline FVIII <40% or unknown, administer first Vonvendi dose with FVIII; monitor VWF and FVIII activity

ContraindicationContraindicated in patients with prior life‑threatening hypersensitivity to Vonvendi or constituents

Vonvendi — duplicate definition reference

Vonvendi (additional reference)FDA‑approved for adults with VWD for on‑demand, perioperative management and routine prophylaxis in severe Type 3 VWD

Clinical trial outcomesPivotal study reported high rates of successful bleed treatment and single‑infusion resolution

MonitoringAssess for anti‑VWF or anti‑FVIII inhibitors if expected activity not attained

Wilate — definition and indications

Wilate — definitionHuman plasma‑derived VWF/FVIII complex indicated for VWD (children and adults) and for hemophilia A in adolescents/adults including prophylaxis

Indication noteUsed when desmopressin fails or is contraindicated; also indicated for perioperative management

Compendial useAcquired von Willebrand syndrome per compendial recommendations

NovoSeven RT / Sevenfact — definitions and indications

NovoSeven RT / Sevenfact — definitionsRecombinant activated factor VII (rFVIIa) products indicated for hemophilia A/B with inhibitors and other specified indications (Sevenfact for >=12 years)

Product distinctionSevenfact expressed in genetically engineered rabbits (contraindicated with rabbit protein allergy); NovoSeven RT produced in hamster cells

Clinical useUsed as bypassing agent for inhibitor patients and specific congenital or acquired factor deficiencies per labeling

Sevenfact — definition and product description

Sevenfact — product descriptionCoagulation factor VIIa (recombinant)-jncw expressed in rabbits; indicated for treatment/control of bleeding in adolescents/adults >=12 with hemophilia A/B with inhibitors

Dose selectionClinical study evaluated 75 mcg/kg and 225 mcg/kg doses with ~86% success for mild/moderate bleeds

ContraindicationContraindicated in patients with known allergy to rabbits or rabbit proteins

NovoSeven RT — definition and product context

NovoSeven RT — definitionRecombinant activated human factor VII (rFVIIa), room‑temperature stable formulation; FDA‑approved for hemophilia with inhibitors, congenital FVII deficiency, Glanzmann’s thrombasthenia, and acquired hemophilia

Clinical noteUsed as bypassing agent; coverage requires hematologist involvement and indication per labeling

MonitoringAssess clinical response and thrombosis risk when used off‑label

rFVIIa / recombinant activated factor VII — definition and investigational use context

rFVIIa — definition and contextRecombinant activated factor VII used as a bypassing hemostatic agent; investigated for various off‑label bleeding indications and rescue therapy

Off‑label use cautionObservational and registry data show variable efficacy and increased thromboembolic risk in some settings

Clinical considerationReserve for life‑threatening or refractory bleeding when conventional measures fail; correct physiologic abnormalities (e.g., pH) to optimize effect

Rescue therapy for intractable bleeding — definition

Rescue therapy definitionUse of rFVIIa or other agents for intractable bleeding unresponsive to routine hemostatic therapy (e.g., after cardiac surgery or in DAH)

EvidenceCase series, registries and small trials report hemostatic responses but thrombotic risk is a concern

DocumentationRequire documentation of failure of standard measures when requesting rescue therapy coverage

Diffuse alveolar hemorrhage (DAH) — definition

Diffuse alveolar hemorrhage (DAH) — definitionLife‑threatening pulmonary bleeding into alveolar spaces seen in hematologic malignancy, autoimmune disease, or post‑transplant; high mortality and limited standard therapies

Therapeutic contextIntrapulmonary or intravenous rFVIIa has been reported as salvage therapy in DAH with variable outcomes

Evidence limitationData are primarily observational or small series; not standard of care per UpToDate guidance

Hereditary Factor X deficiency — definition and Coagadex indication

Hereditary Factor X deficiency — definitionRare bleeding disorder for which Coagadex is FDA‑indicated for prophylaxis, on‑demand treatment, and perioperative management

Perioperative baseline requirementPerioperative management coverage for mild/moderate disease requires baseline Factor X assay >=1%

MonitoringTrough monitoring (>=5 IU/dL) and peak limits recommended during prophylaxis

Factor XIII deficiency — definition and severity threshold

Factor XIII deficiency — definitionRare disorder causing unstable fibrin clot and delayed bleeding; severe deficiency defined as <1 U/dL

Tretten indicationTretten indicated for prophylaxis in congenital FXIII A‑subunit deficiency to achieve trough >=10%

Prophylaxis rationaleLong FXIII half‑life allows monthly dosing to maintain protective troughs

Prothrombin complex concentrate (PCC) — definition

Prothrombin complex concentrate (PCC) — definitionInactivated concentrate of coagulation factors II, IX, and X with variable VII used for urgent reversal of VKA anticoagulation (e.g., Kcentra)

Indication noteKcentra indicated for urgent reversal in adults with acute major bleeding; not indicated without major bleeding

Clinical useGuidelines recommend PCC over plasma for urgent VKA reversal in major bleeding

Antithrombin — definition

Antithrombin — definitionAntithrombin (AT III) is a natural anticoagulant; AT products (Thrombate III, ATryn) used for prevention/treatment in hereditary or acquired deficiency

Product notesATryn indicated for prevention peri‑operative/peri‑partum in hereditary AT deficiency; Thrombate III indicated for treatment/prevention

Clinical implicationTarget AT activity goals during treatment include initial 120% then maintenance >=80% as described elsewhere

Andexxa — definition and indication summary

Andexxa — definitionAndexanet alfa is a recombinant inactivated factor Xa decoy indicated to reverse apixaban and rivaroxaban anticoagulation in life‑threatening or uncontrolled bleeding

Dosing summaryLow‑ and high‑dose bolus and infusion regimens described in labeling based on FXa inhibitor and dose

Indication limitationNot indicated for FXa inhibitors other than apixaban or rivaroxaban per labeling

Idarucizumab (Praxbind) — definition

Idarucizumab (Praxbind) — definitionHumanized monoclonal antibody fragment that binds dabigatran and metabolites to neutralize anticoagulant effect; typically given as 5 g IV

IndicationsEmergency surgery/urgent procedures or life‑threatening/uncontrolled bleeding in dabigatran‑treated patients

DocumentationRecord 5 g IV administration and coagulation assay results (dTT or ECT) where available

EHL factor concentrates — definition and measurement caveats

EHL factor concentrates — definition and caveatsExtended half‑life factor VIII/IX concentrates have modified molecules that can bias assay measurements (under‑ or over‑estimation) depending on assay used

Assay cautionValidated chromogenic or one‑stage assays may be needed; coordinate with laboratory to select appropriate assay

Clinical impactIncorrect assay selection can lead to under‑ or over‑treatment and unnecessary inhibitor testing

VWF:RCo — definition and limitations

VWF:RCo — definition and limitationsRistocetin cofactor assay assessing VWF binding to platelets; limited by high variability and poor sensitivity at low VWF levels

LimitationsHigh coefficient of variation; newer assays preferred when available

Alternative assaysPrefer VWF:GPIbR or VWF:GPIbM assays for better sensitivity and lower variability

VWF:GPIbR / VWF:GPIbM — definition and advantages

VWF:GPIbR / VWF:GPIbM — definitionNewer platelet‑binding assays that do not require ristocetin; offer better sensitivity and lower variability than VWF:RCo

Diagnostic advantageRecommended by ASH/ISTH guidelines for VWD platelet‑binding assessment when available

Use caseUseful in VWD subtyping and when VWF:RCo results are unreliable

salvage — definition reference

Salvage — definition referenceUse of agents (e.g., rFVIIa) as rescue therapy for life‑threatening or refractory bleeding after conventional measures have failed

ContextReported in DAH, post‑HSCT GI bleeding, and refractory perioperative hemorrhage; evidence largely observational

DocumentationRequire demonstration that conventional hemostatic interventions were attempted before salvage therapy

OpenPayer

Clotting Factors

Coverage Criteria for Clotting Factor Products

Relevant Billing and Diagnostic Codes

Prior Authorization, Documentation, and Clinical Actions

Dosing and Administration Regimens

Place in Therapy and Salvage Options

Background and Evidence Summary

Definitions and Terminology

Policy Revision History